Karyopharm Therapeutics Inc. - Common Stock (KPTI)

Karyopharm (KPTI) Q1 2026 Earnings Transcript

Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial cancer, while reporting higher first-quarter revenue and reaffirming full-year guidance. On th

Karyopharm (KPTI) Q2 2025 Earnings Transcript

Karyopharm (KPTI) Q1 2025 Earnings Transcript

Karyopharm (KPTI) Q4 2025 Earnings Call Transcript

Karyopharm (KPTI) Q3 2025 results show a revenue beat but an earnings miss. The stock rose pre-market as investors focus on XPOVIO sales growth and key Phase 3 data due in 2026.

Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and advances Phase 3 selinexor trial.

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.